92 related articles for article (PubMed ID: 8623490)
21. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.
Budde K; Fritsche L; Waiser J; Glander P; Slowinski T; Neumayer HH;
Eur J Med Res; 2005 Apr; 10(4):169-74. PubMed ID: 15946913
[TBL] [Abstract][Full Text] [Related]
22. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
Kovarik JM; Snell GI; Valentine V; Aris R; Chan CK; Schmidli H; Pirron U
J Heart Lung Transplant; 2006 Apr; 25(4):440-6. PubMed ID: 16563975
[TBL] [Abstract][Full Text] [Related]
23. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
24. Concentration control: a key to phase I development of immunosuppressive agents.
Kahan BD
Transplant Proc; 1994 Dec; 26(6):3203-4. PubMed ID: 7998116
[No Abstract] [Full Text] [Related]
25. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
26. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy.
Cohen DS; Fisher RA; Shapiro JH; Goggins WC; Tawes JW; Mills S; Contos M; Ham JM; Schroeder TJ
Transplant Proc; 1996 Oct; 28(5):2501-5. PubMed ID: 8907923
[No Abstract] [Full Text] [Related]
27. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
28. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
29. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.
Olbricht C; Wanner C; Eisenhauer T; Kliem V; Doll R; Boddaert M; O'Grady P; Krekler M; Mangold B; Christians U
Clin Pharmacol Ther; 1997 Sep; 62(3):311-21. PubMed ID: 9333107
[TBL] [Abstract][Full Text] [Related]
30. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Kahan BD
Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
[TBL] [Abstract][Full Text] [Related]
31. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
Massari PU; Grosso S; de Boccardo G; Vásquez MC; Schiavelli RO; Sabbatiello RR; Casadei DH; Rial MC; Jost LJ; Túrin MD; Agost Carreño C A; Maggiora EC; Gadea MM
Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
[No Abstract] [Full Text] [Related]
32. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
Mathew T; Kreis H; Friend P
Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
[TBL] [Abstract][Full Text] [Related]
33. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent.
Firpi RJ; Tran TT; Flores P; Nissen N; Colquhoun S; Shackleton C; Martin P; Vierling JM; Poordad FF
Aliment Pharmacol Ther; 2004 May; 19(9):1033-9. PubMed ID: 15113371
[TBL] [Abstract][Full Text] [Related]
34. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
35. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
[TBL] [Abstract][Full Text] [Related]
36. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
Pescovitz MD
Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
[No Abstract] [Full Text] [Related]
37. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
Lin Y; Waer M
Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
[No Abstract] [Full Text] [Related]
38. Considerations in sirolimus use in the early and late post-transplant periods.
Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
Chueh SC; Wang SM; Lai MK; Chen J
Transplant Proc; 2004 Sep; 36(7):2058-9. PubMed ID: 15518745
[TBL] [Abstract][Full Text] [Related]
40. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
